Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

CLINICAL AND PHARMACOECONOMIC ANALYSIS OF CARBAPENEMS (MEROPENEM, IMIPENEM AND DORIPENEM) IN NOSOCOMIAL PNEUMONIA TREATMENT

Full Text:

Abstract

the article presents the results of a retrospective study conducted in the period from 2008 to 2011 in Moscow’s hospitals. The aim of the study was to compare the clinical and pharmacoeconomical efficacy of carbapenems in nosocomial pneumonia treatment. The study included 87 patients divided into 3 groups according to the therapy (imipenem, meropenem, doripenem). There were no statistically significant differences in clinical efficacy of carbapenems. Pharmacoeconomic analysis showed more profitable use of imipenem.

About the Authors

I. I. Shteynberg
The Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, Moscow
Russian Federation


S. K. Zyryanov
The Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, Moscow
Russian Federation


Yu. B. Belousov
The Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, Moscow
Russian Federation


References

1. Belousov Ju.B., Omel'janovskij V.V., Belousov D.Ju.Farmakojekonomicheskij analiz primenenija doripenema v terapii ventiljator-associirovannoj pnevmonii v sravnenii s meropenemom i imipenemom. Kachestvennaja klinicheskaja praktika. 2008; 3: 85-89.

2. Goncharov V.B., Rudnov V.A., Cherkasov G.V. i soavt. Rezul'taty vnedrenija koncepcii infekcionnoj bezopasnosti v ORIT nejrohirurgicheskogo profilja. Intensivnaja terapija. 2007; 4: 3-7.

3. Ivanov D.V., Bunjatjan N.D., Uteshev D.B., Korsun L.V. Osobennosti antibiotikochuvstvtel'nosti vazhnejshih gramotricatel'nyh vozbuditelej nozokomial'nyh infekcij. Vestnik Rossijskogo gosudarstvennogo medicinskogo universiteta. 2009; 2: 26-29.

4. Ivanov D.V., Egorov A.M. Rasprostranenie i mehanizmy rezistentnosti mikroorganizmov producirujushhih beta-laktamazy, fenotipirovanie potencial'nyh producentov AMRS-beta-laktamaz semejstva Enterobacteriaceae i molekuljarnye mehanizmy ustojchivosti k beta-laktamnym antibiotikam shtammov Enterobacter cloacae, vydelennyh pri vnutribol'nichnyh infekcijah. Biomedicinskaja himija. 2009; 55 (10): 50-60.

5. Reshed'ko G.K., Rjabkova E.L., Kozlov R.S. Sovremennye aspekty jepidemiologii, diagnostiki i lechenija nozokomial'noj pnevmonii. KMAH. 2008; 10 (2): 93-188.

6. Stecjuk O.U., Andreeva I.V. Sovremennye principy antibakterial'noj terapii tjazhelyh i zhizneugrozhajushhih bakterial'nyh infekcij. Farmateka. 2008; 4: 12-17.

7. Chuchalin A.G., Gel'fand B.R. i soavt. Nozokomial'naja pnevmonija u vzroslyh. Nacional'nye rekomendacii. Vestnik anesteziologii i reanimatologii. 2009; 5: 39-59.

8. Castanheira M., Jones R.N., Livermore D.M. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. J. Diagn. Microbiol. Infect. Dis. 2009; 63 (4): 426-433.

9. Chastre J., Wunderink R., Prokocimer P., Lee M., Kaniga K., Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit. Care Med. 2008. 36 (4): 1089-1096.

10. Colardyn F., Faulkner K.L. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J. Antimicrob. Chemother. 1996; 38: 523-537.

11. Craig W. Pharmacodinamic/pharmacokinetic parameters: rationale for antibacterial dosing in mice and men. Clin. Infect. Dis. 1998; 26: 1-12.

12. Garau J., Blanquer J., Cobo L. et al. Prospective, randomized, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur. J. Clin. Microbiol. Infect. Dis. 1997; 16:789-796.

13. Jarvis W.R. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect. Control. Hosp. Epidemiol. 1996; 17 (8): 552-557.

14. Joseph J., Rodvold K.A. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin. Pharmacother. 2008; 9 (4): 561-575.

15. Kollef M.H.et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. J. Critical Care. 2012; 16: P. 218.

16. Kollef MH. Appropriate Empiric Antimicrobial Therapy of Nosocomial Pneumonia: The Role of the Carbapenems. J. Respir. Care. 2004; 49 (12): 1530-1541.

17. Kongnakorn T., Mwamburi M., Merchant S., Akhras K., Caro J.J., Nathwani D. Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation. J. Curr. Med. Res. Opin. 2010; 26 (1): 17-24.

18. Masterton R.G. et al. Guidelines for the management of hospitalacquired pneumonia in the UK: report of the working party on hospitalacquired pneumonia of the British Society for Antimicrobial Chemotherapy. J. Antimicrob. Chemother. 2008; 62 (1): 5-34.

19. McGarry L.J., Merchant S., Nathwani D., Pawar V., Delong K., Thompson D., Akhras K., Ingham M., Weinstein M.C. Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia. J. Med. Econ. 2010; 13 (1): P. 142.

20. Merchant S., Gast C., Nathwani D., Lee M., Quintana A., Ketter N., Friedland I., Ingham M. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. J. Clin. Ther. 2008; 30 (4): 717-733.

21. Niederman M.S., Craven D.E. et al. American Thoracic Society and the Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 2005; 171: 388-416.

22. Nordmann P., Picazo J.J., Mutters R., Korten V., Quintana A., Laeuffer J.M., Seak J.C., Flamm R.K., Morrissey I. Comparative activity of carbapenem testing: the COMPACT study. J. Antimicrob. Chemother. 2011; 66 (5): P. 1070-8.


For citation:


Shteynberg I.I., Zyryanov S.K., Belousov Y.B. CLINICAL AND PHARMACOECONOMIC ANALYSIS OF CARBAPENEMS (MEROPENEM, IMIPENEM AND DORIPENEM) IN NOSOCOMIAL PNEUMONIA TREATMENT. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2014;7(1):14-18. (In Russ.)

Views: 449


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)